Infections
How infectious agents cause disease, the organisms that matter most in practice, and the recognition and management of sepsis, respiratory, urinary, skin and CNS infections — with the scoring tools used to decide how sick someone is.
Classification of Infectious Agents
Bacteria
Single-celled prokaryotes lacking membrane-bound organelles. Structural differences from human cells allow selective targeting with antimicrobials.
- Classified by morphology (cocci, bacilli, spirochetes)
- Cell wall composition determines Gram stain result
- Can produce exotoxins (secreted) or endotoxins (cell wall component)
- Can form spores to survive hostile environments
Structure
- Thick outer peptidoglycan layer
- No outer lipid membrane
- Retains crystal violet stain (purple)
Key Pathogens
- Staphylococcus aureus (inc. MRSA)
- Streptococcus pyogenes (Group A Strep)
- Streptococcus pneumoniae
- Clostridium tetani / botulinum
- Enterococcus spp.
Structure
- Thin peptidoglycan layer
- Outer lipid membrane (contains LPS/endotoxin)
- Does not retain crystal violet (pink)
Key Pathogens
- Escherichia coli
- Pseudomonas aeruginosa
- Neisseria meningitidis / gonorrhoeae
- Klebsiella pneumoniae
- Haemophilus influenzae
Viruses
Non-living infectious agents. Cannot replicate independently — hijack host cell machinery. Classified by nucleic acid type (RNA or DNA) and virion shape.
- Outer envelope comprised of lipids (enveloped) or protein coat (non-enveloped)
- Virion = released viral particle capable of infecting new host
- Highly selective for cell type (tropism)
- No cell wall — most antibiotics ineffective
- Antivirals target specific viral processes (e.g. neuraminidase inhibitors for influenza)
- Can cause lytic, latent or persistent infections
Fungi
Eukaryotic organisms requiring organic carbon for growth. Include single-celled yeasts and multicellular filamentous moulds.
- Yeasts replicate asexually via binary fission
- Moulds grow via extending filaments (hyphae) forming a mycelium
- Aerial hyphae produce spores — readily inhaled
- Common in immunocompromised patients (opportunistic)
- Target: ergosterol in fungal cell membrane (different to human cholesterol)
- Examples: Candida, Aspergillus, Tinea
Parasites
Protozoa
- Single-celled eukaryotes
- Infective stage = trophozoite
- Form cysts to resist hostile environments
- Examples: Plasmodium (malaria), Giardia
Helminths (Worms)
- Multicellular parasites
- Often require more than one host
- Classified as flatworms or roundworms
- Common in areas of poor sanitation
No Treatment Available
Stages of Infection
| Stage | What is happening |
|---|---|
| Incubation | Agent acclimatises to host and begins to replicate. Host is asymptomatic. |
| Prodromal | Agent replicates. Immune response activates. Non-specific symptoms — fever, malaise. |
| Acute | Peak replication. Specific symptoms manifest — cough, rash, lesions, localised pain. |
| Decline | Pathogen numbers reduce — immune response and medical intervention effective. |
| Convalescent | Continued resolution. Patient returns to normal function. Immunity may be established. |
Chain of Infection — Interactive
Infectious Agent
Key Pathogens
Staphylococcus aureus / MRSA
Presentations
- Skin/soft tissue infections
- Bacteraemia & sepsis
- Toxic shock syndrome
- Pneumonia
- Endocarditis
Risk Factors
- Skin breaks/wounds
- Indwelling devices
- Healthcare exposure
- Immunocompromise
- IVDU
Treatment
- MSSA: flucloxacillin
- MRSA: vancomycin
- Source control critical
- Blood cultures before antibiotics
Streptococcus pyogenes (Group A Strep)
Presentations
- Strep throat / pharyngitis
- Cellulitis / erysipelas
- Necrotising fasciitis
- Toxic shock syndrome
- Rheumatic fever (post-infection)
Mechanism
- Exotoxin production
- Immune cross-reactivity with heart tissue → rheumatic fever
- Streptolysins damage host cells
Treatment
- Penicillin (often first-line)
- Amoxicillin for pharyngitis
- Surgery for NF
- Rheumatic fever: long-term penicillin prophylaxis
Escherichia coli & Gram-Negatives
Key Pathogens
- E. coli — UTI, sepsis
- Pseudomonas aeruginosa — burns, HAI
- Klebsiella — pneumonia, UTI
- Neisseria meningitidis — meningitis
Endotoxin (LPS)
- Component of outer membrane
- Released on cell lysis
- Triggers massive inflammation
- Signs often worsen after antibiotics (more lysis)
Treatment
- Cephalosporins / carbapenems
- Culture-guided therapy critical
- Rising resistance (ESBL, CRE)
Toxic Shock Syndrome (TSS)
Time-Critical Presentation
Classic Features
- High-grade fever (>38.9°C)
- Hypotension / shock
- Diffuse erythematous blanching rash (resembles sunburn)
- Desquamation (skin peeling 1–2 weeks later)
- Nausea, vomiting, diarrhoea
- Myalgia, disorientation
- Mucosal hyperaemia
Management Principles
- Aggressive IV fluid resuscitation
- Source control (remove tampon, drain abscess)
- Anti-staphylococcal antibiotics (vancomycin/clindamycin)
- Clindamycin added to inhibit toxin production
- Vasopressors for refractory hypotension
- ICU admission likely required
Infective Endocarditis
Infection and inflammation of the endocardium. Majority of patients have underlying cardiac conditions. Three critical pathogenic elements:
- 1Endocardial damage — usually from pre-existing cardiac condition or instrumentation
- 2Bacteraemia — blood-borne organisms (dental procedures, IV lines, IVDU) reach damaged surface
- 3Vegetation formation — organisms proliferate, forming infected fibrin-platelet vegetations on valves
Key Signs
HIV / AIDS
Pathophysiology
- Flu-like illness (seroconversion)
- Fever, rash, lymphadenopathy
- High viral load
- Occurs weeks after infection
- Often undiagnosed
- Asymptomatic (years)
- Ongoing viral replication
- Gradual CD4 decline
- Person remains infectious
- ART commenced here ideally
- CD4 count <200 cells/µL
- AIDS-defining illnesses
- Systemic fungal infections
- Tuberculosis reactivation
- Kaposi sarcoma, PCP
Management Overview
- Antiretroviral therapy (ART) — Reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors
- ART does not cure HIV but suppresses viral load to undetectable
- Undetectable = Untransmittable (U=U)
- Pre-exposure prophylaxis (PrEP) for high-risk individuals
- Post-exposure prophylaxis (PEP) within 72 hours of exposure
- Standard precautions protect against transmission
Influenza
Pathophysiology & Transmission
- RNA virus — Influenza A and B most clinically significant
- Droplet transmission (coughing, sneezing)
- Incubation 1–4 days, infectious 1 day before symptoms
- Antigenic drift (minor mutation) — annual vaccine variation
- Antigenic shift (major reassortment) — pandemic potential
Clinical Features
- Abrupt onset fever, rigors
- Severe myalgia and headache
- Dry cough, sore throat, rhinorrhoea
- Complications: pneumonia, encephalitis
- High-risk: elderly, immunocompromised, pregnant, chronic disease
Treatment
Herpesvirus Family
| Virus | Primary Infection | Latency Site | Reactivation Triggers | Treatment |
|---|---|---|---|---|
| HSV-1 | Cold sores, oral ulcers | Trigeminal ganglion | Stress, fever, UV light | Aciclovir topical/oral |
| HSV-2 | Genital herpes, lesions | Sacral ganglia | Stress, immunosuppression | Aciclovir, valaciclovir |
| VZV | Varicella (chickenpox) | Dorsal root ganglia | Immunocompromise, age | Aciclovir; vaccine available |
| EBV | Glandular fever (mono) | B lymphocytes | Immunocompromise | Supportive; avoid contact sports |
| CMV | Mild flu-like illness | Monocytes/macrophages | Immunocompromise (transplant) | Ganciclovir IV |
COVID-19 & SARS-CoV-2
Key Features
- RNA coronavirus — binds ACE2 receptor (respiratory, cardiac, renal)
- Droplet and airborne transmission
- Wide clinical spectrum: asymptomatic to critical
- Classic: fever, cough, anosmia/ageusia
- Severe: pneumonia, ARDS, multi-organ failure, coagulopathy
High-Risk Groups & Management
- Elderly, obese, immunocompromised, diabetes, cardiovascular disease
- Supportive: oxygen, prone positioning, dexamethasone (severe)
- Antivirals (nirmatrelvir/ritonavir) for high-risk early in illness
- Vaccination highly protective against severe disease
Common Fungal Infections
| Infection | Organism | Presentation | Population | Treatment |
|---|---|---|---|---|
| Candidiasis | Candida albicans | White plaques (oral thrush), genital, systemic | Immunocompromised, antibiotic use, diabetes | Azoles (fluconazole); echinocandins for systemic |
| Tinea (Ringworm) | Dermatophytes | Dry, itchy, raised red rings; affects skin/nails/scalp | Any; close contact, shared facilities | Topical azoles; oral terbinafine for nails |
| Tinea Versicolor | Malassezia | Cosmetic pigment disruption, hypo/hyperpigmented patches | Young adults, warm/humid climates | Topical selenium sulfide or azoles |
| Aspergillosis | Aspergillus | Pulmonary infiltrates, haemoptysis, sinusitis | Severely immunocompromised (transplant, haematological malignancy) | Voriconazole (often first-line) |
| Cryptococcus | Cryptococcus neoformans | Meningitis, pneumonia | HIV/AIDS (CD4 <100) | Amphotericin B + flucytosine |
Malaria
Life-Threatening — Notifiable Disease
Life Cycle & Transmission
- Transmitted via female Anopheles mosquito bite
- Sporozoites → liver (asymptomatic maturation)
- Merozoites → RBC invasion → RBC lysis (cyclic fever)
- Gametocytes taken up by mosquito to complete cycle
Clinical Features & Management
- Cyclical fever, rigors, sweating (48/72 hr cycles)
- Severe anaemia, splenomegaly, jaundice
- P. falciparum: cerebral malaria, ARDS, renal failure
- Artemisinin combination therapy (ACT) — often first-line
- IV artesunate for severe malaria
- Prevention: bed nets, repellent, chemoprophylaxis
Definition (Sepsis-3)
Severity Escalation
Pathophysiology
Circulatory Compromise Cascade
- 1Systemic inflammation → Nitric oxide (NO) released throughout body
- 2NO → Vasodilation — reduces venous return (preload) → ↓ stroke volume & cardiac output. Directly impairs myocardial contractility.
- 3↑ Vessel permeability → fluid leaks from intravascular space → reduced circulating volume
- 4Coagulopathy — ↑ procoagulant factors, microthrombi in small vessels → impaired capillary perfusion
- 5↓ RBC flexibility → impaired oxygen delivery → organ dysfunction → failure if untreated
Common Sources
- Lower respiratory tract (pneumonia) — most common
- Urinary tract — most common in elderly
- Abdominal (bowel perforation, cholangitis)
- Skin / soft tissue (cellulitis, NF)
- No source found in up to one-third of cases
Risk Factors
- Age >65 or very young (<1 year)
- Immunocompromised (malignancy, steroids, HIV)
- Recent surgery or invasive procedures
- Indwelling catheters / IV lines
- Diabetes mellitus, chronic renal failure
- Alcohol/drug use, pregnancy
qSOFA Score — Interactive Calculator
qSOFA Guidance
SOFA Score — Organ Systems
SOFA is a score commonly used to quantify organ dysfunction in sepsis. It is primarily an in-hospital tool; the systems below are scored from clinical and laboratory parameters.
| System | Parameter | Score 1 | Score 2 | Score 3–4 |
|---|---|---|---|---|
| Respiratory | PaO2/FiO2 ratio | <400 | <300 | <200 / <100 (ventilated) |
| Cardiovascular | MAP / vasopressors | MAP <70 | Dopamine <5 | Higher dose vasopressors |
| Renal | Creatinine / UO | 110–170 µmol/L | 171–299 | >300 / UO <0.5mL/kg/hr |
| Liver | Bilirubin | 20–32 µmol/L | 33–101 | >102 / >204 |
| CNS | GCS | 13–14 | 10–12 | <10 / <6 |
| Coagulation | Platelets (×10³/µL) | <150 | <100 | <50 / <20 |
SOFA Score Mortality
Septic Shock Definition
Sepsis 6 Bundle
The Sepsis 6 is a care bundle commonly used to structure early sepsis management — aim to complete all six actions within one hour of recognition. Adoption and specific actions vary by region; follow your local sepsis guidelines.
- Blood cultures x2 (before antibiotics if possible — do not delay treatment)
- Blood tests — lactate level, FBC, CRP, UEC, LFTs, coagulation
- Urine output measurement (urinary catheter provides most reliable measurement)
Lactate >2 mmol/L indicates tissue hypoperfusion even if BP appears normal.
- High-flow oxygen (target SpO2 >94%; caution with COPD)
- IV fluid resuscitation — crystalloid 30mL/kg bolus (restores preload)
- Empirical IV antibiotics (broad-spectrum; within 1 hour of recognition)
Vasopressors and inotropes if BP is not maintained with IV fluids.
Pre-Hospital Management
Urinary Tract Infections
Pathophysiology & Risk
- Bacteria most common cause — predominantly E. coli (opportunistic translocation from GI tract)
- Higher risk in females: short urethra, proximity of GU and GI tract openings
- Innate defences: acidic urine pH, voiding (shearing force), endogenous microbiota
- Healthcare-acquired UTIs: much harder to treat due to antimicrobial resistance
Risk Factors
- Indwelling urinary catheters (CAUTI)
- Anatomical abnormalities / urological obstruction
- Sexual intercourse (females)
- Pregnancy
- Diabetes mellitus
- Incomplete bladder emptying
- Infection confined to bladder/urethra
- Dysuria (painful urination)
- Urinary frequency and urgency
- Suprapubic pain or pressure
- Haematuria (blood in urine)
- No systemic features
- Infection of renal pelvis and parenchyma
- Flank / loin pain (often severe)
- Fever >38°C, rigors
- Nausea and vomiting
- May have lower UTI symptoms
- Risk of sepsis — IV antibiotics often required
Red Flags — Seek Urgent Assessment
Diagnosis
- Mid-stream urine (MSU) for UTI — avoids contamination from colonised distal urethra
- Dipstick: leucocytes, nitrites, blood, protein
- MC&S (microscopy, culture & sensitivity) guides antibiotic choice
- Blood cultures if signs of sepsis
Management
- Increased oral fluid intake
- Analgesia (paracetamol, NSAIDs)
- Antibiotics based on culture sensitivity and site of infection
- Uncomplicated lower UTI: trimethoprim or cefalexin (oral)
- Pyelonephritis / sepsis: IV cephalosporins or gentamicin
- Prevention: post-coital voiding, reduce catheter time in situ
Sexually Transmitted Infections (STIs)
Key Principles
| Infection | Organism | Presentation | Complications | Treatment |
|---|---|---|---|---|
| Chlamydia | Chlamydia trachomatis | Often asymptomatic; discharge, dysuria, pelvic pain | Pelvic inflammatory disease (PID), infertility, neonatal infection | Azithromycin or doxycycline |
| Gonorrhoea | Neisseria gonorrhoeae | 50% asymptomatic; purulent discharge, dysuria | PID, epididymitis, disseminated gonococcal infection | Ceftriaxone IM (rising resistance) |
| Syphilis | Treponema pallidum | Primary: painless chancre. Secondary: rash, fever. Tertiary: cardiovascular/neurological | Neurosyphilis, cardiovascular syphilis, congenital syphilis | Penicillin (all stages) |
| Genital Herpes | HSV-2 (mainly) | Painful genital ulcers/vesicles, dysuria; recurrent | Neonatal herpes if active during delivery | Aciclovir (no cure; reduces episodes) |
| HPV | Human papillomavirus | Genital warts; often asymptomatic (high-risk strains) | Cervical, oropharyngeal, anorectal cancers (high-risk strains) | No antiviral; wart treatment, vaccination |
| HIV | HIV-1 / HIV-2 retrovirus | Acute: flu-like. Chronic: asymptomatic. AIDS: OIs | AIDS, opportunistic infections, malignancies | Antiretroviral therapy (ART) — lifelong |
At-Risk Populations
Pneumonia
Classified by organism
- Bacterial (most common)
- Viral (influenza, COVID-19, RSV)
- Fungal (immunocompromised)
- Aspiration (mixed organisms)
- Develops in a community setting
- Common: S. pneumoniae, Mycoplasma, H. influenzae
- Most respond to oral antibiotics
- Onset >48 hours after admission
- Gram-negative and resistant organisms
- Higher mortality, broader antibiotics
Transmission Routes
- Inhalation of aerosols or respiratory droplets
- Spread from upper respiratory tract infection
- Aspiration of oropharyngeal secretions
- Haematogenous spread (less common)
Clinical Presentation
- Cough ± productive (purulent or rust-coloured sputum)
- Breathlessness, pleuritic chest pain
- Fever, rigors, sweating
- Myalgia, malaise, reduced appetite
- Auscultation: crackles (crepitations), bronchial breath sounds, reduced air entry
CURB-65 Severity Score — Interactive
CURB-65 is a score commonly used to assess community-acquired pneumonia severity and guide admission decisions. One point for each criterion present.
Tuberculosis (TB)
Airborne Precautions Required
- Develops in immunologically naive individuals
- Often asymptomatic or mild respiratory illness
- Ghon complex forms (calcified primary focus)
- Most cases contained by immune response
- Latent TB: no symptoms, not infectious
- Arises in previously sensitised hosts
- Reactivation of latent infection (immunosuppression, HIV, malnutrition)
- Classic: productive cough, haemoptysis, night sweats, weight loss
- Cavitating lesions on chest X-ray
- Treatment: RIPE regimen (6 months)
Bacterial Skin Infections
| Infection | Depth | Causative Organism | Features | Management |
|---|---|---|---|---|
| Impetigo | Superficial epidermis | S. aureus, S. pyogenes | Highly contagious; bullous (fluid-filled) or non-bullous (honey-coloured crust); insect bites/eczema predispose | Topical mupirocin; oral flucloxacillin for widespread |
| Folliculitis | Hair follicle | S. aureus | Pustules around hair follicles; shaving, friction predispose | Usually self-limiting; topical antibiotics |
| Erysipelas | Dermis (superficial) | S. pyogenes | Bright red, well-demarcated erythematous rash; systemic infection — fever, chills | Penicillin; hospitalisation often required |
| Cellulitis | Deep dermis + subcutaneous | S. aureus, S. pyogenes | Poorly demarcated erythema, warmth, oedema, tenderness; systemic features; risk with diabetes/immunocompromise | Oral flucloxacillin; IV if systemic, facial or rapidly spreading |
Necrotising Fasciitis
Surgical Emergency — Time-Critical
Warning Signs
- Pain disproportionate to visible wound
- Rapid spread of erythema beyond initial margins
- Skin becomes dusky, blue-grey, then necrotic
- Crepitus (gas in tissues) — pathognomonic
- Severe systemic sepsis
- Anaesthesia of affected skin (nerve destruction)
Management
- Immediate hospital transport — pre-notify surgical team
- IV access, fluid resuscitation, high-flow oxygen
- Blood cultures + broad-spectrum IV antibiotics
- Emergency surgical debridement (definitive treatment)
- ICU admission post-operatively
Fungal & Parasitic Skin Infections
- Infection of keratinised skin layers
- Keratin is the nutrient source
- Dry, itchy, raised red margins with central clearing
- Tinea pedis (athlete's foot), capitis, unguium (nails)
- Topical or oral antifungals
- Warm, moist, macerated areas
- Red skin with white edges (satellite lesions)
- Intertrigo, nappy rash, oral thrush
- Risk: diabetes, antibiotics, obesity
- Topical clotrimazole or nystatin
- Scabies: mite burrows into epidermis — intensely pruritic, worse at night
- Burrow tracks between fingers, wrists, genitalia
- Pediculosis: lice of head, body, pubic area
- Highly contagious — contact precautions
- Permethrin cream / ivermectin
Wound Infections
Disruption to skin integrity allows pathogen entry. The inflammatory response to wounding creates serous exudate and tissue damage. Biofilm formation is a hallmark of chronic wounds and significantly impairs antimicrobial penetration.
Wound Infection Spectrum
- Colonisation — organisms present without inflammatory response or tissue damage
- Infection — organisms replicate, immune response activated, tissue damage occurs
- Systemic infection — bacteria enter bloodstream, sepsis risk
Burn Wounds
- Significant tissue damage makes burns highly susceptible to infection
- Loss of skin barrier function
- Infections often healthcare-associated
- Strict aseptic technique, wound dressings critical
Meningitis
Classic Triad — Time-Critical
- Less common but more dangerous than viral
- Key organisms: N. meningitidis, S. pneumoniae, Listeria (neonates/elderly)
- Rapid onset — hours
- CSF: cloudy, high WCC (neutrophils), low glucose, high protein
- Treatment: IV ceftriaxone (empirical) + dexamethasone
- Contact precautions; droplet precautions for meningococcal
- Vaccine-preventable (meningococcal B and ACWY)
- More common — usually less severe
- Key organisms: enteroviruses, HSV, mumps
- Gradual onset — days
- CSF: clear, elevated lymphocytes, normal/low glucose, mildly raised protein
- Treatment: supportive; aciclovir for HSV meningitis
- Usually self-limiting in immunocompetent hosts
Encephalitis
Inflammation and infection of brain tissue itself — less common than meningitis but causes extensive necrosis of brain tissue. Clinical features overlap with meningitis but altered consciousness and focal neurological deficits are more prominent.
- Altered consciousness (confusion, stupor, coma)
- Focal neurological deficits
- Seizures (often the presenting feature)
- Personality and behavioural changes
- Most common cause: HSV encephalitis (temporal lobe)
- Treatment: IV aciclovir (start empirically — do not wait for CSF)
- MRI brain + EEG + CSF analysis
- Rabies also causes viral encephalitis — vaccine preventable
Other Serious CNS Infections
| Infection | Organism | Mechanism | Key Features | Treatment / Prevention |
|---|---|---|---|---|
| Tetanus | Clostridium tetani | Spores germinate in deep wounds (anaerobic). Neurotoxin (tetanospasmin) blocks inhibitory neurotransmitters → sustained muscle contraction | Lockjaw (trismus), opisthotonus, risus sardonicus, severe spasms, autonomic instability | Wound debridement, tetanus immunoglobulin, metronidazole, muscle relaxants. Vaccine-preventable. |
| Botulism | Clostridium botulinum | Toxin targets the peripheral nervous system at the neuromuscular junction — blocks acetylcholine release → flaccid paralysis | Descending flaccid paralysis, diplopia, dysarthria, dysphagia, respiratory failure | Antitoxin, mechanical ventilation if respiratory compromise. Food-borne, wound, or infant types. |
| Rabies | Rabies virus (lyssavirus) | Replicates in muscle, travels retrogradely along peripheral nerves to brain → encephalitis | Initially flu-like, then agitation, hydrophobia, aerophobia, paralysis, coma — almost universally fatal once symptomatic | Post-exposure prophylaxis (rabies immunoglobulin + vaccine) must be given before symptoms. Vaccine-preventable. |
| Polio | Poliovirus | Faecal-oral transmission. CNS invasion in <1% of cases — destroys anterior horn motor neurons | Majority asymptomatic. Paralytic polio: acute asymmetric flaccid paralysis — may cause permanent disability | No antiviral. Vaccine-preventable (OPV/IPV). Near-eradicated globally. |
| Prion Diseases | Prions (misfolded proteins) | Conformational change in normal brain prion protein (PrP) → progressive neurodegeneration (spongiform encephalopathy) | Rapidly progressive dementia, ataxia, myoclonus, psychiatric symptoms. Universally fatal. | No treatment available. Most resistant known pathogen. Requires alkaline detergent + extended steam sterilisation for decontamination. |
Antibacterial Drug Classes
| Mechanism | Drug Class | Examples | Spectrum | Key Notes |
|---|---|---|---|---|
| Cell Wall Synthesis Inhibition | Beta-lactams — Penicillins | Amoxicillin, flucloxacillin, piperacillin | Gram positive mainly; some broad | Allergy common; bactericidal |
| Beta-lactams — Cephalosporins | Cefalexin (1st), ceftriaxone (3rd) | Broad spectrum; varies by generation | Useful for severe infections and meningitis | |
| Beta-lactams — Carbapenems | Meropenem, ertapenem | Very broad — reserve for resistant organisms | Last-resort; protect from overuse | |
| Glycopeptides | Vancomycin, teicoplanin | Gram positive (inc. MRSA) | IV only; renal monitoring required | |
| Protein Synthesis Inhibition | Macrolides | Azithromycin, clarithromycin | Atypical organisms, Gram positive | Useful for pneumonia, STIs; bacteriostatic |
| Tetracyclines | Doxycycline | Broad; atypicals, STIs | Avoid in pregnancy and children under 12 | |
| Aminoglycosides | Gentamicin, tobramycin | Gram negative | Oto/nephrotoxic; monitor levels | |
| Cell Membrane Disruption | Polymyxins | Colistin | Gram negative MDR organisms | Last-resort; nephrotoxic |
| DNA / Metabolite Inhibition | Fluoroquinolones | Ciprofloxacin, norfloxacin | Broad spectrum; UTI, GI, respiratory | Avoid in children; tendon rupture risk |
| Nitroimidazoles | Metronidazole | Anaerobes, protozoa | Inhibits DNA replication; abdominal infections |
Other Antimicrobial Classes
- Azoles (fluconazole, voriconazole) — inhibit ergosterol synthesis
- Polyenes (amphotericin B) — bind ergosterol, disrupt membrane
- Echinocandins (caspofungin) — inhibit cell wall glucan synthesis
- Target ergosterol (not human cholesterol) — selective toxicity
- Anti-HIV (ART) — reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors
- Influenza — neuraminidase inhibitors (oseltamivir)
- Herpesviruses — aciclovir, valaciclovir (inhibit DNA replication)
- COVID-19 — nirmatrelvir/ritonavir (protease inhibitor)
- Antimalarials — artemisinin, chloroquine (inhibit nucleic acid/protein synthesis)
- Antihelminthics — albendazole (inhibit tubulin polymerisation)
- Antiprotozoals — metronidazole (inhibit DNA replication)
- Ectoparasiticides — permethrin, ivermectin
Antimicrobial Stewardship Principles
Antimicrobial stewardship is the safe and effective prescription of antimicrobial agents to improve patient outcomes, reduce adverse effects (including resistance emergence), and ensure cost-effective therapy.
- Culture before treatment — collect samples first where possible
- Evidence-based indications — treat only where antimicrobials improve outcomes
- Narrowest spectrum — minimise collateral damage to normal flora
- Appropriate dosage — must achieve therapeutic levels at site of infection
- Minimise duration — shorter courses reduce resistance development
- Monotherapy preferred in most cases
- Resistance arises from overuse, underuse and misuse — including incomplete courses
- Resistance spreads via transformation, conjugation (plasmid transfer), and transduction (bacteriophage)
Antimicrobial Resistance — Global Threat
Keep going
Reading it through once is the easy part. These are the ways to make it stick.